Apollo Life Sciences announces it has achieved a major breakthrough by successfully lowering blood glucose levels in diabetic rats with oral insulin, using its proprietary oral delivery technology, Oradel TM . This makes needle-free insulin for diabetes treatment now possible.
Life Therapeutics (ASX: LFE)(PNK: LFEFY) announced today that it has completed the sale of the Frenchs Forest building for A$9.25m to a fund controlled by MacarthurCook Ltd (ASX: MCK).
Leading tissue and cord blood banking company CyGenics Ltd. (ASX: CYN) today announced that it will focus primarily on its core revenue-generating tissue and cord blood banking businesses, which continue to show substantial growth in both numbers of clients and revenue.
Life Therapeutics (ASX: LFE) will supply Cangene Corporation with Anti-Anthrax plasma for Cangene to produce an Anti-Anthrax hyperimmune for the U.S. Department of Health and Human Services.
The August 2006 edition of our Health & Life Science Quarterly Blue Book profiles niche life sciences companies, with a focus on company strategies, key projects and significant milestones.
Life Therapeutics (ASX: LFE) announced today that it has signed leases to open two new donor collection centers: one in Sacramento and the second in Long Beach in California. It is expected that these centers will become operational at the end of August 2006.
Life Therapeutics (ASX: LFE) announced today that it has exchanged contracts with MacarthurCook Ltd (ASX: MCK) for the sale of its Frenchs Forest building.
